Chemical Delivery Systems: Evaluation of Physicochemical Properties and Enzymatic Stability of Phenylephrone Derivatives

REFERENCES

• Bodor N. I. K. ReddyThe use of retrometabolic drug design concepts in ophthalmic drug discovery. Ocular Therapeutics and Drug Delivery, . Technomic, PA 1996; 335–361
   Google Scholar
• Reddy I. K., Bodor N. S. Novel approaches to design and deliver safe and effective anti-glaucoma agents to the eye. Adv. Drug Del. Rev. 1994; 14: 251–267
   Web of Science ®Google Scholar
• Bodor N. B. TestaNovel approaches to the design of safer drugs: Soft drugs and site specific chemical delivery systems. Advances in Drug Research, . Academic Press, London 1984; 255–331
   Google Scholar
• Bodor N., Brewster M. E. Problems of delivery of drugs to the brain. Pharm. Ther. 1983; 19: 337–386
   Web of Science ®Google Scholar
• Schoenwald R. D. A. K. MitraChemical delivery systems with enhanced pharmacokinetic properties. Ophthalmic Drug Delivery Systems, . Marcel Dekker, New York 1993; 307–330
   Google Scholar
• El-Koussi A. A., Bodor N. Formulation of propranolol in the iris-ciliary body from its propranolol ketoxime precursor—a potential antiglaucoma drug. Int. J. Pharm. 1989; 53: 189–194
   Web of Science ®Google Scholar
• Maurice D. M., Mishima S. M. L. SearsOcular pharmacokinetics. Pharmacology of the Eye, . Springer, New York 1984; 19–116
   Google Scholar
• Das N. D., Shichi H. Enzymes of mercapturate synthesis and other drug-metabolizing reactions—specific localization in the eye. Exp. Eye Res. 1981; 33: 525–533
   PubMed Web of Science ®Google Scholar
• Bodor N., Visor G. Formation of adrenaline in the iris-ciliary body from adrenalone diesters. Exp. Eye Res. 1984; 38: 621–626
   PubMed Web of Science ®Google Scholar
• Bodor N., Kaminski J. J., Roller R. G. Improved delivery through biological membranes. VI. Potent sympathomimetic adrenalone derivatives. Int. J. Pharm. 1978; 1: 189–196
   Google Scholar
• Bodor N., Visor G. Improved delivery through biological membranes. XVII. A site-specific chemical delivery system as short-acting mydriatic agent. Pharm. Res. 1984; 168–172
   PubMed Web of Science ®Google Scholar
• Bergamini M. V. W., Murray D. L., Krause P. D. Pivalyl phenylephrine (PPE), mydriatic prodrug of phenylephrine with reduced cardiovascular effects. Invest. Ophthalmol. Vis. Sci. 1979; 20: 187–191
   Google Scholar
• Kumar V., Schoenwald R. D., Chien D. S., Packer A. J., Choi W. W. Systemic absorption and cardiovascular effects of phenylephrine eyedrops. Am. J. Ophthalmol. 1985; 99: 180–184
   PubMed Web of Science ®Google Scholar
• Tammara V. K., Crider M. A. I. K. ReddyProdrugs: A chemical approach to ocular drug delivery. Ocular Therapeutics and Drug Delivery, . Technomic, PA 1996; 285–334
   Google Scholar
• Mindel J. S., Shaikewitz S. T., Podos S. M. Is phenylephrine pivalate a prodrug?. Arch. Ophthalmol. 1980; 98: 2220–2223
   PubMedGoogle Scholar
• Yuan S. S., Bodor N. Synthesis and activity of R-(−)-m-trimethylacetoxy-alpha-[(methylamino)methyl] benzyl alcohol hydrochloride: a prodrug form of (R)-(−)-phenylephrine. J. Pharm. Sci. 1976; 65: 929–931
   PubMed Web of Science ®Google Scholar
• Schoenwald R. D., Folk J. C., Kumar V., Piper J. C. In vivo comparison of phenylephrine and phenylephrine oxazolidine instilled in the monkey eye. J. Ocular Pharmacol. 1987; 3(4)333–340
   PubMedGoogle Scholar
• Reddy I. K. Design and evaluation of site-specific Chemical Delivery Systems to the eye. Ph.D. Dissertation, University of Florida, Gainesville, FL 1989
   Google Scholar
• Martorell C., Calpena A. C., Escribano E., Poblet J. M., Freixas J. Influence of the chromatographic capacityfactor (log k′) as an index of lipophilicity in the antibacterial activity of a series of 6-fluoroquinolones. Relationship between physico-chemical and structural properties and their hydrophobicity. J. Chromatogr. A. 1993; 655: 177–184
   PubMed Web of Science ®Google Scholar
• Boudeville P., Bona M., Burgot J. L. Correlations between n-octanol/water partition coefficients and RP-HPLC capacity factors of 1,2-dithiole-3-thiones and 1,2-dithiol-3-ones. J. Pharm. Sci. 1996; 85(9)990–998
   PubMed Web of Science ®Google Scholar
• Yang S., Bumgarner J. G., Kruk L. F. R., Khaledi M. G. Quantitative structure-activity relationship studies with micellar electrokinetic chromatography. Influence of surfactant type and mixed micelles on estimation of hydrophobicity and bioavailability. J. Chromatogr. A. 1996; 721: 323–335
   PubMed Web of Science ®Google Scholar
• Bundgaard H., Moss J. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res. 1990; 7: 885–892
   PubMed Web of Science ®Google Scholar
• Hansen L. B., Christrup L. L., Bundgaard H. Ketobemidone prodrugs for buccal delivery. Acta Pharm. Nord. 1991; 3: 77–82
   PubMedGoogle Scholar
• Aungst B. J., Blake J. A., Rogers N. J., Saitoh H., Hussain M. A., Ensinger C. L., Pruitt J. R. Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist. Pharm. Res. 1995; 12: 763–767
   PubMed Web of Science ®Google Scholar
• Bundgaard H., Rasmussen G. J. Prodrugs of peptides. 11. Chemical and enzymatic hydrolysis kinetics of N-acyloxymethyl derivatives of a peptide-like bond. Pharm. Res. 1991; 8: 1238–1242
   PubMed Web of Science ®Google Scholar
• Harkness J. E., Wagner J. E. The Biology of Medicine of Rabbits and Rodents. 2nd ed., Lea and Febiger, Philadelphia 1983
   Google Scholar
• Patel J. U., Prankerd R. J., Sloan K. B. A prodrug approach to increasing the oral potency of phenolic drug. 1. Synthesis, characterization, and stability of an o-(imidomethyl) derivative of 17β-estradiol. J. Pharm. Sci. 1994; 83: 1477–1481
   PubMed Web of Science ®Google Scholar